Moderna commits 100 million COVID-19 vaccine doses to the US

pharmafile | August 12, 2020 | News story | Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Moderna, US, Vaccine, pharma 

Moderna continues to rise to meet the demands of the pandemic, signing a new deal with the US Government to supply 100 million doses of its messenger RNA (mRNA) vaccine candidate for the prevention of COVID-19.

The agreement commits up to $1.525 billion to cover the manufacture and delivery of candidate mRNA-1273, and includes “incentive payments” to encourage that the vaccine is delivered as quickly as possible.

This follows the previous agreement of up to $955 million signed by Moderna with the Biomedical Advanced Research and Development Authority (BARDA), meaning the US Government has now committed $2.48 billion in total to the research and delivery of the vaccine candidate under its Operation Warp Speed.

“For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” commented Alex Azar, US Secretary of Health and Human Services. “With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people.”

Under the terms of the deal, the US Government will also have the option to reserve a further 400 million doses of the vaccine.

“We appreciate the confidence of the US Government in our mRNA vaccine platform and the continued support,” remarked Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …

Latest content